Literature DB >> 12633918

Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine.

Olga V Lopatko1, Jason M White, Alice Huber, Walter Ling.   

Abstract

In maintenance patients methadone has been shown to produce considerable changes in opioid effects and withdrawal over the dosing interval. As a partial agonist buprenorphine may be expected to produce smaller changes, but the nature and magnitude of these changes have only been described for single doses. In the present study opioid effects and withdrawal were described in patients maintained on buprenorphine. Twenty four opioid dependent subjects were administered 16 mg buprenorphine tablets sublingually for 10 days. On day 10 plasma samples were collected and physiological, subjective and observer-rated measures collected pre-dose and at 14 time points during the dosing interval. No significant respiratory depression was observed. Consistent with the partial agonist properties of buprenorphine, other physiological and subjective changes were also of small magnitude. However, even at a once daily dose of 16 mg some patients experienced significant opioid withdrawal that was maximal at the end of the dosing interval. Buprenorphine maintenance should be associated with a high level of safety and a low level of disruption caused by changing opioid effects over the dosing interval, but some patients may require high doses or other strategies to completely suppress withdrawal.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12633918     DOI: 10.1016/s0376-8716(02)00322-8

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  10 in total

Review 1.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Probuphine® (buprenorphine implant): a promising candidate in opioid dependence.

Authors:  Preeti Barnwal; Saibal Das; Somnath Mondal; Anand Ramasamy; Tanay Maiti; Arunava Saha
Journal:  Ther Adv Psychopharmacol       Date:  2016-12-19

3.  Non-medical use of opioids among HIV-infected opioid dependent individuals on opioid maintenance treatment: the need for a more comprehensive approach.

Authors:  Perrine Roux; Patrizia M Carrieri; Julien Cohen; Isabelle Ravaux; Bruno Spire; Michael Gossop; Sandra D Comer
Journal:  Harm Reduct J       Date:  2011-11-28

4.  Buprenorphine and its formulations: a comprehensive review.

Authors:  Salomon Poliwoda; Nazir Noor; Jack S Jenkins; Cain W Stark; Mattie Steib; Jamal Hasoon; Giustino Varrassi; Ivan Urits; Omar Viswanath; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-08-20

Review 5.  Pharmacological maintenance treatments of opiate addiction.

Authors:  James Bell
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

6.  Novel Formulations of Buprenorphine for Treatment of Opioid Use Disorder.

Authors:  Richard N Rosenthal
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-04-10

7.  Lower buprenorphine elimination rate constant is associated with lower opioid use.

Authors:  Hesham Farouk Elarabi; Amanda J Lee; Abdu Adem; Abuelgasim Elrasheed; John Marsden; Hamad Al Ghaferi
Journal:  Psychopharmacology (Berl)       Date:  2022-08-12       Impact factor: 4.415

8.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

Review 9.  Pharmacologic treatments for opioid dependence: detoxification and maintenance options.

Authors:  Herbert D Kleber
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

Review 10.  Advances in the delivery of buprenorphine for opioid dependence.

Authors:  Richard N Rosenthal; Viral V Goradia
Journal:  Drug Des Devel Ther       Date:  2017-08-28       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.